ANI Pharmaceuticals, Inc.

As of October 10, 2025, ANI Pharmaceuticals has a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite a bearish monthly RSI, and has significantly outperformed the S&P 500 year-to-date with a return of 62.43%.

As of October 10, 2025, ANI Pharmaceuticals has a mildly bullish technical trend, supported by strong weekly indicators but tempered by a bearish monthly RSI, and has significantly outperformed the S&P 500 year-to-date with a return of 62.43%.

As of August 7, 2025, ANI Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and moving averages, despite a bearish weekly RSI indicating short-term caution, while significantly outperforming the S&P 500 over one and three years.

As of November 8, 2024, ANI Pharmaceuticals, Inc. is considered overvalued with a risky valuation grade, reflected by a Price to Book Value of 3.22, an EV to EBITDA ratio of 23.83, a negative ROE of -3.27%, and poor financial health compared to peers, despite recent stock performance.

As of June 6, 2025, ANI Pharmaceuticals, Inc. shows a mildly bullish trend, supported by daily moving averages and bullish Bollinger Bands, despite some bearish signals on the weekly and monthly MACD and KST.

As of March 2022, ANI Pharmaceuticals, Inc. is led by Chairman Patrick Walsh and CEO Nikhil Lalwani, with independent directors including Robert Brown, Thomas Haughey, David Nash, Thomas Penn, and Antonio Pera on the Board.

ANI Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription drugs. As of March 2025, it reported net sales of $197 million and a net profit of $14 million.

As of Jun 18, ANI Pharmaceuticals, Inc. has a market capitalization of $1.38 billion, with net sales of $674.06 million and a net profit of -$22.62 million over the last four quarters. Shareholder's funds are $403.68 million, and total assets amount to $1.28 billion.